Integra Resources Corp. (ITRG)
NYSEAMERICAN: ITRG · Real-Time Price · USD
1.480
+0.040 (2.78%)
Aug 1, 2025, 4:00 PM - Market closed
Revance Therapeutics Stock Forecast
Stock Price Forecast
The 1 analyst with a 12-month price forecast for Revance Therapeutics stock has a target of 3.25, which predicts a 119.59% increase from the current stock price of 1.48.
Price Target: $3.25 (+119.59%)
Analyst Consensus: Strong Buy
Analyst Ratings
According to 1 stock analyst, the rating for Revance Therapeutics is "Strong Buy". This means that the analyst believes this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Feb '25 | Mar '25 | Apr '25 | May '25 | Jun '25 | Jul '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 1 | 1 | 1 | 1 | 1 | 1 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $2.75 → $3.25 | Strong Buy | Maintains | $2.75 → $3.25 | +119.59% | Jul 18, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $2.75 | Strong Buy | Reiterates | $2.75 | +85.81% | Apr 23, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $2 → $2.75 | Strong Buy | Maintains | $2 → $2.75 | +85.81% | Mar 27, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $3.75 → $2 | Strong Buy | Maintains | $3.75 → $2 | +35.14% | Jan 15, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $3.75 | Strong Buy | Reiterates | $3.75 | +153.38% | Oct 31, 2024 |
Financial Forecast
Revenue This Year
270.96M
from 30.35M
Increased by 792.78%
Revenue Next Year
245.46M
from 270.96M
Decreased by -9.41%
EPS This Year
0.22
from -0.10
EPS Next Year
0.01
from 0.22
Decreased by -96.19%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|
| High | 250.2M | 250.2M | 346.5M | |
| Avg | 245.5M | 245.5M | 264.3M | |
| Low | 233.6M | 233.6M | 179.4M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|
| High | 724.5% | 1.9% | 41.2% | |
| Avg | 708.8% | - | 7.7% | |
| Low | 669.5% | -4.9% | -26.9% |
EPS Forecast
| EPS | 2025 | 2026 | 2028 |
|---|---|---|---|
| High | 0.03 | -0.14 | 1.07 |
| Avg | 0.01 | -0.14 | 1.05 |
| Low | -0.01 | -0.13 | 1.00 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2028 |
|---|---|---|---|
| High | - | - | - |
| Avg | - | - | - |
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.